EvidenceHunt, an AI-powered medical research platform transforming how professionals pinpoint, analyze, and utilize evidence, has completed a €1.2m funding round led by Keen Venture Partners, Dff.ventures, and Slimmer AI. Notable angel investors joined the consortium, including Jeroen Tas (former Chief Strategy and Innovation Officer at Philips), Dinko Valerio (former CEO and Founder of Crucell), and James Shannon (former Head of Global Drug Development at Novartis).
Launched 1.5 years ago after two years of research and scientific validation, this platform has grown organically to a global user base of 25,000 active and returning users. Healthcare professionals, medical science experts, researchers, and students from over 90 countries regularly engage with the system.
Searching for medical evidence traditionally consumes significant time and effort. Professionals often spend hours crafting complex queries and sifting through PubMed, guidelines, and protocols to locate reliable answers. These inefficiencies result in lost time and slow down evidence-based decision-making.
EvidenceHunt optimizes this process by delivering clear, summarized answers within seconds, complete with cited sources and trackable details for instant verification. Navigating scientific literature, once requiring extensive manual review, now takes only seconds. Extracting precise data from vast publications, akin to locating a needle in a haystack, becomes effortless. Literature reviews that previously required days or weeks can now be completed within hours. Reports indicate users save up to five hours per week, depending on profession and specific use cases.
“As a medical doctor and PhD, I know firsthand how frustrating it can be to spend countless hours navigating PubMed, guidelines, and protocols. From day one, we built EvidenceHunt to mimic domain-specific logic and processes for evaluating and interpreting literature. But we aim to do more than just save time - we provide clear answers that users can trace back to credible sources. Unlike generic AI platforms, our goal with EvidenceHunt is not to be a black box; it’s designed to empower users with transparency and reliability, which are essential for adoption and for earning the trust of the medical community,” said Philippe Habets, CEO of EvidenceHunt.
Investor JC Heyneke from Slimmer AI and former GM at Elsevier stated: “EvidenceHunt addresses a clear pain point for users across various segments worldwide. By integrating into institutional workflows and with institutional data, and applying the latest LLM technology in a powerful vertical-AI SaaS solution, EvidenceHunt taps into a large and growing market.”
Image credit: EvidenceHunt